Vodis Pharmaceuticals Inc, Closes Final Tranche Of Non-Brokered Private Placement

2015-12-18 0500 PT - News Release

VP Close 2015-09-17 C$ 0.165

 Mr. Otto Folprecht reports


December 18, 2015 - Vancouver, British Columbia – Vodis Pharmaceuticals Inc. (the “Company” or “Vodis”) (CSE: VP / FSE: 1JV) announces the closing of the third and final tranche of its previously announced non-brokered private placement of up to 12,000,000 shares by issuing 4,010,000 common shares at a price of $0.10 for gross proceeds of $401,000. The shares issued in the final tranche have a four month and one day hold period expiring on April 18, 2016.

In the first and second tranches, the Company issued 2,170,000 common shares on November 6th, 2015 for gross proceeds of $217,000 and 4,925,000 common shares on November 20th, 2015 for gross proceeds of $492,500, which together with the final tranche raised total gross proceeds of $1,110,500. The total number of shares issued in the private placement was 11,105,000.

In connection with the final tranche, the Company paid finders’ fee of 10% cash and 10% finders’ warrants for a total of $32,600 and 326,000 non-transferable share purchase warrants (“Finders’ Warrant”) to Canaccord Genuity Corp., Wolverton Securities Ltd. and a third party. Each Finders’ Warrant entitles the holder to purchase one common share of the Company at an exercise price of $0.10 for a two year period, expiring on December 17, 2017.

Otto Folprecht CEO and Director commented; “We are extremely pleased that the investor community continues to support the direction the Company has taken as we continue to invest in our Washington State assets to meet the expansion requirements of our tenants in a booming Washington State marijuana market.

The fact that the private placement was quickly filled and oversubscribed is a strong indication that the Vodis business model of bringing a state-of-the-art turn-key production facility is in line with our investors’ expectations”.

The proceeds of the private placement will be used for expansion into Washington State, USA and general working capital purposes.

About Vodis Pharmaceutics Inc.

Vodis is one of North Americas foremost brand names in the medical and recreational marijuana business with operations in both the US and Canada. Its master grow teams have consistently won or placed at each competition they have entered with their “VIP” brand.  The Company, with facilities in BC and Washington State, is also actively looking into expansion opportunities in other countries and US states.

While Vodis and its subsidiaries cannot have any interest whatsoever in any proceeds as a result of production, processing or retail activities in the United States, it can license its brand, production and consulting services to approved Washington State license holders to ensure that all products produced under the Vodis Pharmaceuticals program and/or associated under the VIP brand meet or exceed the Vodis brand quality standards.  

For further information please contact:

Richard Schnoor

Head of Corporate Communications

Vodis Pharmaceuticals Inc.

8788 River Road

Delta, BC V4G 1B5

Direct: 1-866-210-1420 ext. 110

Web: www.vodis.ca

Forward-Looking Information:

Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “expects” or “it is expected”, or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including: the use of proceeds of this financing. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update any forward-looking statements or forward-looking information that is incorporated by reference herein, except as required by applicable securities laws.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.




Jordana Casey

  • Page 1 of 61